

CONTENTS

Chapter 1

What is a Biologic?.....	1
A Brief History of Biologics Regulation in the United States.....	3
Recent Changes in the Government’s Approach to Biologics Regulation.....	6
Regulatory Definition of a Biological Product.....	13
General Comparison of Drug and Biologic Characteristics.....	15
Product Classification and the FDA’s Intercenter Agreements.....	16
The Importance of Product Classification: Impact on Development Strategy.....	18
The Meaning of “Follow-On” Biologics.....	20
References.....	22

Chapter 2

Preclinical Safety Assessment of Therapeutic Proteins and Monoclonal Antibodies.....	25
Preclinical Development of Biologics.....	26
Biologics-Specific Concepts.....	27
Preclinical Studies to Support the Safety of Biologics.....	29
The Timing of Preclinical Studies Relative to Clinical Trials.....	33
Summary.....	33
References.....	34

Chapter 3

The Biological IND.....	35
FDA Organization and IND Submissions.....	36
Types of IND Submissions.....	37
Before Submitting an IND.....	39
Example Meeting Request Sheet.....	40
The Original IND Submission.....	41
Contents of the IND.....	46
INDs for Gene Therapies.....	61
The Submission and Review of the IND.....	62
Amendments to the IND.....	63
Electronic INDs.....	68
Summary.....	71
Acknowledgments.....	71
References.....	71

Chapter 4

The Biological IND Review Process.....	73
The FDA and Regulating Biological Products: Recent History and Agency Structure.....	74
FDA Announces CDER/CBER Consolidation.....	78
A Look at the Structure of CBER and CDER for IND Reviews.....	80
CBER Structure.....	80
The Office of Tissues and Advanced Therapies (formerly known as Office of Cellular, Tissue and Gene Therapies).....	82
CDER’s Structure for Biological IND Reviews.....	84
The Review Process for INDs.....	87
CBER and the IND Review Process.....	88
CDER and the IND Review Process for Biological Therapeutic Products.....	91
The IND and the 30-Day IND Review Clock.....	94
The Clinical Hold.....	96
IND Status.....	102

Chapter 5

Clinical Testing of Biologically Derived Therapeutics	105
Phases of Clinical Drug Development.....	105
References	123

Chapter 6

The Clinical Evaluation of Preventive Vaccines	125
Federal Regulations Pertaining to Vaccines.....	126
U.S. FDA Regulations Relevant to the Manufacture, Product Quality and Clinical Testing of Vaccines*	127
Overview of Clinical Evaluation.....	127
Phases of Clinical Development.....	128
Serious Adverse Events (SAEs) During Clinical Development	131
Additional Considerations for Safety Data.....	139
FDA Advisory Committee Deliberations	140
Postlicensure Studies.....	140
Postlicensure Surveillance	140
Regulatory Initiatives for Accelerated Vaccine Development During COVID-19 Pandemic	141
Acknowledgments	145
References	145

Chapter 7

Good Clinical Practices (GCP)	153
Information Sheets: Guidance for Institutional Review Boards and Clinical Investigators.....	155
Responsibilities of the Sponsor.....	162
Responsibilities of Investigators.....	170
The Institutional Review Board (IRB)	173
Informed Consent	176
References	182

Chapter 8

The Biological License Application (BLA)	185
A Short History of the FDA's Licensing Process for Biologics	187
An Introduction to the BLA: Content and Format Requirements and Form 356h.....	191
The Content of the BLA.....	198
CBER and the eBLA Program.....	230
Amending the License Application.....	232
References	233

Chapter 9

Manufacturing Arrangements For Biological Products.....	235
Biologics Establishment Registration	236
Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) Establishments	237
The Biotech Explosion, Industry Consolidation, and Biological Manufacturing.....	237
The FDA Redefines "Manufacturer".....	238
Sole Manufacturing.....	239
Current Cooperative Manufacturing Arrangements for Licensed Biologics.....	241
Facility Inspections.....	252
References	255

Chapter 10

The Biological License Application (BLA) Review Process.....	259
The BLA Review Process.....	266
The BLA Managed Review Process Within CBER.....	268
Sponsor Rights during the License Application Review Process.....	293
References.....	303

Chapter 11

Post-licensure Requirements.....	305
Adverse Experience-Related Regulatory Definitions.....	309
Changes in AE Reporting Requirements.....	319
Expedited Reporting of Additional Safety Information.....	319
Lot Release.....	327
Current Good Manufacturing Practice (cGMP) Standards for Biological Products.....	331
Written Procedures for the investigation should include the following:.....	338
Written records of the investigation should include:.....	338
General Reporting Requirements.....	339
Phase 4 Study Commitments.....	357
References.....	360

Chapter 12

Bioresearch Monitoring Program for Biologics.....	367
A Brief History of the Bioresearch Monitoring Program.....	367
Recent Issues for the FDA's BIMO Program.....	368
An Overview of CBER's Bioresearch Monitoring Program.....	374
The Clinical Investigator Compliance Program.....	375
The Clinical Sponsor/Monitor Compliance Program.....	377
The Institutional Review Board (IRB) Compliance Program.....	379
The Nonclinical Laboratory Compliance Program.....	380
CDER's Bioresearch Monitoring Program.....	381
References.....	382

Chapter 13

Biologics and the Regulation of Combination Products.....	383
Defining Biologics, Drugs, and Devices.....	384
CBER Action Plans.....	385
Combination Products and Gaining CBER Approval.....	389
Safe Medical Devices Act (SMDA) of 1990.....	389
Table. RFD Determinations by OCP and Workload Trends: FY 2013 to FY 2018.....	398
Table. Workload at OCP by Combination Product Category Number in FY 2018. Combination.....	398
PDUFA and Various Classes of CBER-Regulated Products.....	399
Risk-Based Quality and Safety Management throughout the Lifecycle of Combination Products.....	403
References.....	405

Chapter 14

Special Topics in the Development of Biologically Derived Therapeutics.....	407
References.....	435

Chapter 15

Biosimilar Products	445
Biosimilar Development, Review, and Approval Processes.....	446
Interchangeable Products: Definition, Regulatory Review and Approval Process.....	448
Post-marketing or Post-authorization Surveillance Requirements	451
Nomenclature	453
FDA-Approved Biosimilar Products.....	454
The Biologics Price Competition and Innovation Act	455
An Abbreviated Approval Pathway for Biological Products.....	456
References	457

About Barnett International	463
--	-----

About Cambridge Healthtech Institute	463
---	-----